(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
MeiraGTx Holdings (MGTX) reported a Q2 net loss Thursday of $0.76 per diluted share, wider than its loss of $0.46 a year earlier. Four analysts polled by...
MeiraGTx Holdings (MGTX) said Wednesday it has obtained a term loan from Perceptive Advisors for up to $100 million, including $75 million upon closing....
MeiraGTx Holdings (MGTX) said Tuesday it has seen encouraging data from a phase 1/2 clinical study of botaretigene sparoparvovec to treat patients with...
| Address | 430 East 29th Street New York, New York 10016 |
| Phone | +1.646.860.7985 |
| Number of Employees | 68 |
| Recent SEC Filing | 08/11/2022 8-K |
| President, Chief Executive Officer & Director | Alexandria Forbes |
| Chief Operating & Financial Officer | Richard Giroux |
| Chief Medical Officer | Robert K. Zeldin |
| Chief Development Officer | Stuart Naylor |
| Price Open | $10.54 |
| Previous Close | $10.49 |
| 52 Week Range | $6.59 - 24.89 |
| Market Capitalization | $503.0 M |
| Shares Outstanding | 44.7 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 11/09/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.96 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | -224.55% |
| Return on Equity | -47.00% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
